<DOC>
	<DOC>NCT01715909</DOC>
	<brief_summary>This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (&lt;) 13 years of age, with confirmed influenza infection. Participants will be randomized to receive either the standard dose or triple dose of oseltamivir orally daily for a minimum of 5 days and up to 20 days. Infants &lt;1 year of age will be randomized to the standard dose arm only.</brief_summary>
	<brief_title>A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Male or female children, &lt;13 years of age Rapid influenza diagnostic test (RIDT), polymerase chain reaction (PCR), or viral culture positive for influenza Immunocompromised Symptoms/signs suggestive of influenza like illness (ILI) Less than or equal to (&lt;/=) 96 hours between onset of ILI and first dose of study drug Clinical evidence of severe hepatic impairment Infants &lt;2 weeks of age or, if born preterm, with postmenstrual age (PMA) &lt;36 weeks Clinical evidence of significant renal impairment Allergy to oseltamivir or excipients Hereditary fructose intolerance Received antiviral treatment with activity against influenza (for example amantadine, rimantadine, oseltamivir, laninamivir, peramivir, zanamivir, and ribavirin) or probenecid medication within 2 weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>